Pharmaceutical

STAT+: Sana to lay off nearly a third of staff, de-prio...

Sana Biotechnology said Tuesday that it would lay off nearly a third of its empl...

STAT+: A fraught question for the children of Alzheimer...

A fraught question for the children of Alzheimer’s: Is it coming for us?

STAT+: How doctors and nurses shape Google’s AI, DEA ex...

In the latest edition of STAT's Health Tech newsletter: How doctors and nurses s...

To protect chickens from bird flu, researchers try to C...

In a new study, scientists sought to engineer bird flu resistance in chickens.

Want a biotech buyout? Target cancer

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Pharmalittle: Weight-loss drugs fuel boom for fi...

Contract manufacturers are investing billions to expand or build factories to fi...

STAT+: Akero’s treatment for NASH falls short in cirrho...

Akero Therapeutics said Tuesday that an experimental medicine failed to show a s...

The ‘model-eat-model world’ of clinical AI: How predict...

New research shows how AI models can become a victim of their own success, sendi...

Opinion: Connecticut’s comptroller explains his thinkin...

The state of Connecticut expects to spend more than $30 million on GLP-1s in 202...

With a rare immunodeficiency disease, a performer and p...

Learning the hard way how to live with a rare inherited immunodeficiency, chroni...

Stroke deaths, despite advances in prevention, are set ...

Despite advances in prevention, stroke deaths are projected to near 10 million g...

STAT+: Bristol ‘take-under’ of Mirati is not so great f...

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics fr...

STAT+: FDA rejects Alnylam’s heart disease treatment ov...

The FDA rejected an Alnylam therapy for an increasingly prevalent heart disease,...

STAT+: Delfi launches its blood test to screen for lung...

Taking aim at a major killer, the well-funded startup Delfi Diagnostics launches...

STAT+: A Q&A with the global head of Boehringer Ingelhe...

STAT spoke with the global head of Boehringer Ingelheim's innovation unit, about...

Amgen acquires Horizon Therapeutics for $27.8bn

Amgen has acquired Ireland-based biotechnology company Horizon Therapeutics in ...